{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:12:19Z","timestamp":1783001539110,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.japh.2023.08.012","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T17:18:06Z","timestamp":1692465486000},"page":"1821-1825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8939-3573","authenticated-orcid":false,"given":"Francine","family":"Mendoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8449-6629","authenticated-orcid":false,"given":"Rita","family":"Parsiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.japh.2023.08.012_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-017-0918-8","article-title":"Weight management in patients with type 1 diabetes and obesity","volume":"17","author":"Mottalib","year":"2017","journal-title":"Curr Diab Rep"},{"issue":"5","key":"10.1016\/j.japh.2023.08.012_bib2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.japh.2023.08.012_bib3","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","article-title":"Temporal patterns in overweight and obesity in type 1 diabetes","volume":"27","author":"Conway","year":"2010","journal-title":"Diabet Med"},{"issue":"14","key":"10.1016\/j.japh.2023.08.012_bib4","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0002-9149(99)80683-3","article-title":"Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial","volume":"75","year":"1995","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.japh.2023.08.012_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/MED.0000000000000555","article-title":"Advancing Care for Type 1 Diabetes, Obesity Network (ACT1ON). Pharmacological therapies to address obesity in type 1 diabetes","volume":"27","author":"Casu","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"21","key":"10.1016\/j.japh.2023.08.012_bib6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","article-title":"Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus","volume":"76","author":"Guyton","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.japh.2023.08.012_bib7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1742-7843.2009.00380.x","article-title":"The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control","volume":"105","author":"Jacobsen","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.japh.2023.08.012_bib8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.japh.2023.08.012_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003363","article-title":"Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study","volume":"3","author":"Lund","year":"2008","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.japh.2023.08.012_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.japh.2023.08.012_bib11","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/dom.14121","article-title":"Exenatide extended release in patients with type 1 diabetes with and without residual insulin production","volume":"22","author":"Herold","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.japh.2023.08.012_bib12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the lira Pump trial-a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.japh.2023.08.012_bib13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1177\/1060028016651279","article-title":"GLP-1 agonists in type 1 diabetes mellitus","volume":"50","author":"Janzen","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.japh.2023.08.012_bib14","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/dom.14567","article-title":"Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes","volume":"24","author":"Schmidt","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.japh.2023.08.012_bib15","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/dom.14050","article-title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","volume":"22","author":"Dub\u00e9","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.japh.2023.08.012_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101433","article-title":"Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): a randomized double-blind placebo-controlled trial","volume":"49","author":"Thivolet","year":"2023","journal-title":"Diabetes Metab"},{"issue":"3","key":"10.1016\/j.japh.2023.08.012_bib17","first-page":"1","article-title":"Impact of adding semaglutide in a person with type 1 diabetes: a case report","volume":"5","author":"Sofra","year":"2019","journal-title":"Diabetes Update"},{"issue":"5","key":"10.1016\/j.japh.2023.08.012_bib18","first-page":"363","article-title":"A\u00a0naltrexone-induced increase in insulin requirement","volume":"14","author":"Marrazzi","year":"1994","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.japh.2023.08.012_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"10295","key":"10.1016\/j.japh.2023.08.012_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.japh.2023.08.012_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1210\/clinem\/dgab722","article-title":"Effects of tirzepatide, a dual GIP and GLP-1 RA, on lipid and metabolite profiles in subjects with Type 2 diabetes","volume":"107","author":"Pirro","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.japh.2023.08.012_bib22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.13979","volume":"22","author":"Frias","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.japh.2023.08.012_bib23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.japh.2023.08.012_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"suppl 1","key":"10.1016\/j.japh.2023.08.012_bib25","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc23-S006","article-title":"6. Glycemic targets: standards of care in Diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123002649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123002649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:07Z","timestamp":1761544387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123002649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1544319123002649"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.08.012","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}